omniture
logo
Search
Ascletis Pharma Inc./歌礼生物科技（杭州)有限公司
Media Room

Latest News

rss

Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients

HANGZHOU, China and SHAOXING, China, Nov. 10, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2021-11-10 08:30 3864

Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study

HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672)...

2021-11-09 08:33 4266

Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma...

2021-11-08 08:30 4324

Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH

SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis ...

2021-11-01 08:30 3601

Gannex Announces Clinical and Preclinical Data of Four NASH Programs to be Presented in Oral or Poster Presentation at The Liver Meeting® 2021 by American Association for the Study of Liver Diseases

SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2021-10-13 20:30 4356

Ascletis Announces Results of the Phase IIa trial of ASC22 (Envafolimab) in Patients with Chronic Hepatitis B to be Presented in Oral Parallel Session at The Liver Meeting(R) 2021 by American Association for the Study of Liver Diseases

HANGZHOU and SHAOXING, China, Oct. 12, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) annou...

2021-10-12 08:30 4505

Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRβ Agonist ASC41

SHANGHAI, Sept. 8, 2021 /PRNewswire/ -- Gannex, a wholly owned company of Ascletis Pharma Inc. (HKE...

2021-09-08 08:30 4519

Gannex Announces Clinical Trial Application of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA

SHANGHAI, Sept. 6, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis...

2021-09-06 08:30 4231
1 ... 45678